Drug intelligence / Profile preview

AMLOGOOD AT

Development stage
Unknown
Lead developer
GoodMed Healthcare
Modality
Small Molecules
Administration
Oral
01

Overview

AMLOGOOD AT is a fixed-dose combination therapy developed by GoodMed Healthcare, containing the calcium channel blocker amlodipine and the HMG-CoA reductase inhibitor atorvastatin. Amlodipine is an L-type calcium channel blocker that treats hypertension by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral resistance. Atorvastatin is a statin that treats dyslipidemia by inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, thereby lowering LDL cholesterol levels. This oral tablet is approved for the management of both hypertension and dyslipidemia in patients who require concurrent treatment for both conditions.

Brand names
AMLOGOOD AT 10AMLOGOOD AT 20
Other names
AMLOGOOD AT10AMLOGOOD AT20Amlodipine 5 mg + Atorvastatin 10 mgAmlodipine 5 mg + Atorvastatin 20 mg
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on AMLOGOOD AT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMLOGOOD AT.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call